Conference Handbook 2015

Translating UK scientific excellence into global therapeutic strategies

MedImmune is the worldwide biologics research and development arm of AstraZeneca, with its headquarters in Gaithersburg, Maryland (US) and a major R&D Centre in Cambridge (UK). MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines.

MedImmuneCambridgededicated to innovation

Employing approximately 500 people, the MedImmune Cambridge site is a major R&D hub supporting the research and early development of the biologics portfolio, contributing to all of the MedImmune therapy areas.

MedImmune has a robust pipeline of over 120 biologic medicines in R&D, with 35 in clinical stage development. The company’s marketed products include Synagis(r) (palivizumab) and Fluenz(r) (live attenuated influenza vaccine, LAIV).

By 2016, MedImmune will be joined in Cambridge by AstraZeneca’s new UK-based global research and development centre, and corporate headquarters will be located at the Cambridge Biomedical Campus - bringing together AstraZeneca’s small molecule and MedImmune’s biologics research and development.

ON Helix 2015 Sponsors contentsWelcome 4

Advisory Board 6-7

Keynote Speakers 8-9

Floor Plan and Exhibitor List 10-11

Speaker Profiles 12-18

Programme 14-15

Exhibitor Profiles 21-27

Official Supporters

Media Partners

Platinum Sponsors

Partners

Gold Sponsors

Corporate Patron

Corporate Sponsors

Media Partners

Silver Sponsors

Partnering powered by

3sponsors

The One Nucleus team is so excited to be bringing our much acclaimed Translational Research conference back to the Wellcome Trust Genome Campus. Those of you familiar with ON Helix will be aware that we couldn’t host you here last year because the Conference Centre was being transformed. We are the first event taking place since the incredible make-over and we hope you enjoy the new experience and all it has to offer.

One of the key issues described by many researchers is how to overcome the innovation gaps on the translational research pathway. This includes identifying barriers on which to concentrate, finding funding and meeting the right networks.

These topics are of course covered by many conferences, but with ON Helix, One Nucleus brings together all these elements in one event under one roof for one day. Excellence in translational research is a core skill of many One Nucleus members and it seemed entirely appropriate that we should showcase that excellence to the UK and wider community; especially if it will stimulate and inspire young and emerging companies to follow in the footsteps of the people you will hear and learn from today.

ON Helix aims to inform delegates of how to turn early stage inventions and ideas into innovative health treatments. We will present the UK landscape of the business environment, funding, scientific and clinical research excellence. It will be a unique knowledge-sharing environment between academia and business.

ON Helix was launched in July 2013 to great acclaim by Sir William Castell, Chair of the Wellcome Trust, who described it as ‘a great day with a fantastic line-up (and) a great showcase for the strength of biomedical innovation’. Sir Mike Rawlins, now Chair of the MHRA followed up by declaring it ‘THE translational event in the UK – it’s terrific’. So we decided to make it an annual fixture.

You can expect stimulating keynote speeches, exceptional world class case study examples of collaborations and technologies and plenty of networking.

The One Nucleus team and I know you will make full use of the presentations, debate, networking and the exhibitions to catch up with old friends and make some new ones, update yourselves on trends in the sector and create and scope out new business opportunities.

I would like to take this opportunity to thank our fantastic ON Helix Advisory Board for all their support, all our sponsors and speakers for making it possible and of course you, our delegates, for bringing the event to life.

I wish everyone an excellent event.

Harriet FearCEO, One Nucleus

Dear ON Helix Participant,

Welcome to our Translational Research Conference: ON Helix

4 welcome

Partnering for scientific leadership

What science can do

Circulating tumour DNAAstraZeneca has pioneered the use of circulating tumour DNA (ctDNA) in the diagnosis of cancer. Pieces of DNA break off from a tumour and circulate in the bloodstream where they can be analysed to give genetic information about a patient’s tumour. This allows healthcare professionals to determine the right treatment for the patient using a non-invasive blood test.

At AstraZeneca, we believe in the power of what science can do to transform serious diseases like cancer, heart disease, diabetes, COPD and asthma. We also know that breakthrough science doesn’t happen in isolation. It happens through partnership.

Our expertise spans the entire life-cycle of a medicine and we have a rare combination of discovery and development strengths in small molecules and biologics, immunotherapies, protein engineering technologies and devices. These are reinforced by a strong focus on translational science and personalised healthcare.

To find out more, visit astrazeneca.com/Partnering

AZ Partnering AD_A4.indd 1 03/07/2015 17:29

Jane Dancer

Chief Operating Officer, F-star Jane joined F-star as their Chief Operating Officer in April 2012. Prior to that she was VP Business Development at Cellzome and Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)) Jane spent the first part of her career in the agrochemical industry where she held research and project management roles in Aventis Crop Science, AgrEvo UK Ltd and Schering Agrochemicals Ltd,. Jane has an MBA from The Judge Institute of Management Studies, University of Cambridge and a PhD and degree in Natural Sciences from the University of Cambridge.

Hakan Goker Investment Director, MS Ventures Hakan Goker (Ph.D.) is a director at MS Ventures, the corporate venture capital fund of Merck Serono. Previously, Hakan was a partner at Aescap Venture, investing in European private biotechnology and medical technology companies. Prior to Aescap, he was at Atlas Venture in London until their cessation of European operations. He was instrumental in the creation, financing, business and R&D strategy of various companies including Orphazyme (DK), F Star (NL), Actogenix (BE), Bicycle Therapeutics (UK), Nimbus Discovery (US), Lumavita (CH), Nitec now Horizon Pharma (CH/US), Protaffin (AU/UK), and Egalet (DK). Hakan received his PhD in oncology from the Institute of Cancer Research/ University of London, UK and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan is a board member of Synaffix BV and is acting CBO of Asceneuron SA.

Eric Karran Director of Research Strategy, Alzheimer’s Research UK Eric joined Alzheimer’s Research UK in 2012 and has responsibility for high-level external representation of our charity as well as driving forward our research strategy. Eric has extensive dementia research experience gained from working in the pharmaceutical industry, holding senior positions in Neuroscience drug discovery research groups (most recently Chief Scientific Officer at Janssen Pharmaceuticals in Belgium), focusing on finding therapeutics for Alzheimer’s disease. He has interacted widely with leading academic groups in the UK, Europe and the USA, as well as working with public funding agencies such as the MRC.

One Nucleus Aline Charpentier, Business Development Manager Nadia Shivji, Events and Business Development Manager Aline joined One Nucleus in 2010 and since then has managed a range of European and internal projects, the most exciting being the launch of ON Helix in 2013 and seeing its success increasing over the years. Nadia joined One Nucleus in December after her Postdoctoral Fellowship at the University of Cambridge. Since her PhD at the Babraham Institute, she has worked in both academia and industry including companies such as Domainex and MedImmune. Nadia is now the Events and Business Development Manager at One Nucleus.

6 advisory board

Alan Palmer CSO, MS Therapeutics | One Nucleus Board Member

Alan Palmer is an internationally recognised neuroscientist and a serial entrepreneur, whose career has focussed on neurodegenerative disorders and their treatment.  Currently, he is (i) a Board member of Cerebroscience Ltd, MS Therapeutics Ltd (MST) and One Nucleus Ltd; (ii) a visiting Professor at both University College London and the University of Reading; (iii) Life Science Entrepreneur in Residence at the University of Bristol; (iv) a Fellow of the Society of Biology; and (iv) a member of the Scientific Advisory Board of both GE Healthcare Medical Diagnostics Ltd and Pharmidex Pharmaceutical Services Ltd. (Pharmidex). Alan has over 100 peer-reviewed papers to his name, 35 of which are highly cited (> 50 citations); total number of citations > 6,000. Formerly, Alan was: (i) voted London Biotechnology Network Entrepreneur of the Year; (ii) Chairman of the Society for Medicines Research;. (iii) a member of the UK Government’s Biotech Pharma Sector Advisory Group; (iv) Group Leader, Wyeth Research Ltd; (v) Principal Investigator, Alzheimer’s Disease Research Centre, University of Pittsburgh Medical School  (UPMC); and (vi). Principal Investigator, Head Injury Research Centre, UPMC. He has founded or co-founded a number of companies, including Cerebroscience, MST, New Medicines Discovery, Pharmidex, Cerexus, and Cerebrus (now Vernalis).

Rob Pinnock Director of Scientific Liason, Merck Sharp & Dohme Rob joined MSD’s licensing team in Sept 2007 and since mid 2008 his remit is to identify partnering opportunities in the UK, Ireland, Portugal and Spain. Before joining MSD Rob worked for a year in Cambridge University on neuronal injury & prosthetics. He spent time in Biotech between 2004-6, advancing programs in CV, metabolic disease & pain from concept to clinic. Previously he held positions of increasing seniority in Parke Davis,Cambridge,UK, until their acquisition by Pfizer. In 2001 he moved to Pfizer research laboratories in Ann Arbor, Michigan, as senior director for CNS Molecular Science. Collaborations were an important part of Rob’s mandate at Parke-Davis / Pfizer. Before he joined the pharmaceutical industry Rob trained in Southampton and spent several years as a research fellow at the MRC and University of Cambridge.

David Tapolczay CEO, Medical Research Council Technology Group (MRCT)

Dr David Tapolczay has 28 years experience of R&D management; his past roles include joint worldwide head of chemistry for Zeneca agrochemicals and senior manager of chemical development for Glaxo. He was responsible for the rapid growth of Cambridge Discovery Chemistry and was a key figure in two successful sales of the company initially to Oxford Molecular and then Millennium Pharmaceuticals. Post this last acquisition David was VP of Pharmaceutical Sciences with responsibility for over 230 scientists. On leaving Millennium David was a founder of Pharmorphix Ltd which was acquired by Sigma Aldrich Fine Chemicals in August 2006. He has also been involved with the start up of 5 companies all of which are still trading and one of which has been AIM listed. He was most recently VP of Technology Development for GSK pharmaceuticals and is currently the Chief Executive Officer of the Medical Research Council Technology Group (MRCT). David has an international reputation in the pharmaceutical industry as well as an outstanding academic track record with a considerable number of patents and publications. He was a visiting Professor at Sussex University and has previously held the position of visiting lecturer at Nottingham, Reading and Durham Universities and a member of both the Technical Opportunities Panel and the User Panel of the EPSRC. In addition he is a non executive director for several biotech companies.

7advisory board

Bahija JallalExecutive Vice President AstraZeneca and Head of MedImmune Dr. Bahija Jallal is Executive Vice President of AstraZeneca and Head of MedImmune, a global biologics research and development organization with locations in Gaithersburg, California and Cambridge, UK. She is a member of the senior executive team at AstraZeneca reporting to the CEO. Dr. Jallal joined MedImmune in March 2006.

Dr. Jallal is passionate about leading and shaping MedImmune’s rich pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardio-vascular and metabolic diseases and pain to ultimately develop new medicines for patients.

Dr. Jallal is a member of the Board of Directors of the University of Maryland Health Sciences Research Park Corporation, a non-profit organization that manages biomedical research development at the BioPark. She was recently appointed to the Board of Trustees of The Johns Hopkins University.

Dr. Jallal has authored over 70 peer-reviewed publications and has over 15 patents. She is a member of the American Association of Cancer Research, the American Association of Science and the Pharmacogenomics Working Group. She serves as a member of the Board of Directors for the Association of Women in Science and an advisory member of the Healthcare Business Women’s Association. She was named one of FierceBiotech’s “Women in Biotech” and a “Women Who Mean Business” from the Washington Business Journal. In 2013, Dr. Jallal earned the Grace Award from the Cancer Research Institute. In 2014, Dr. Jallal earned Maryland’s International Business Leadership Award and was the Scientific Honoree for the 2015 Life without Lupus Gala.

Prior to joining MedImmune, Dr. Jallal worked with Chiron Corporation where she served as vice president, drug assessment and development, and successfully established the company’s translational medicine group. Prior to Chiron Corporation, she worked at Sugen, Inc. where she held positions of increasing responsibility leading to senior director, research.

Dr. Jallal received a master’s degree in biology from the Universite de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.

Nicolas SireauChairman and CEO, AKU Society

Dr Nicolas Sireau is Chairman and CEO of the AKU Society, a medical charity that works to find a cure for and support patients with AKU (also called Black Bone Disease), an ultra rare disease that affects his two sons (www.akusociety.org).

He is Co-founder and Chairman of Findacure (www.findacure.org.uk), a new social enterprise that raises awareness into and helps patients with fundamental diseases: extreme and exceptional diseases that advance our understanding of medicine and help us discover potential new treatments (www.findacure.org.uk).

He is a committee member of Rare Disease UK, the national alliance of rare disease groups in the UK, and of the International Rare Disease Research Consortium (IRDiRC). He is also is a founding member of the Cambridge Rare Disease Network.

He is a fellow of the Ashoka fellowship of social entrepreneurs and of the Royal Society of Arts. He is the editor of ‘Rare Diseases: Challenges and Opportunities for Social Entrepreneurs’ (Greenleaf, 2013) and co-editor of ‘The Rare Diseases Patient Group Handbook’ (forthcoming). He is co-founder of the Vincent Foundation for brain injury and a former non-executive Director of GenSeq, a bioinformatics company.

8 keynote speakers

Farid Bidgoli Associate Director of Market Access, Merck Sharp & Dohme

Farid Bidgoli, BSc Pharmaceutical Chemistry, is the Associate Director of Market Access for MSD leading on Real World Evidence generation for MSD in the UK. Prior to Joining MSD, Farid worked for the Association of British Pharmaceutical Industry where he led Industry’s position on Innovation Health and Wealth, working closely with NHS England on the Implementation and evolution of policy to drive the uptake of Innovation in the NHS.

Farid spent 6 years at AstraZeneca where he held various roles. In his most recent position, he supported the development of customer marketing and solutions in the US whilst leading the corporate strategy on customer collaborations in the UK, assisting healthcare organisations improve services and pathways to help drive efficiencies in care, spend and improvements in patient outcomes in Respiratory, Diabetes and Cardiovascular disease. His work has led to sustainable change within the NHS in over 30 Clinical Commissioning Groups and has led to reduced hospital admissions, reductions in length of stay, efficiencies in prescribing and improvements in patient reported outcomes. These achievements have been published by the Department of Health and Farid has given many presentations for NICE, NHS England and the ABPI.

Prior to joining the Pharmaceutical industry, Farid worked in the Middle East securing the distribution rights for Fast Moving Consumer Goods with companies such as Philips, Mars and Tefal in countries such as Turkey, Iraq and Iran, before which he led Phase I clinical trial programmes and pharmacokinetic studies for Covance Laboratories.

George Freeman MP-Parliamentary Under Secretary of State for Life Sciences

George was elected to Parliament in 2010 after a 15 year career across the life sciences sector, in particular working with hospitals, clinical researchers, patient groups, and biomedical research companies to pioneer novel healthcare innovations.

Following his election to Parliament in 2010, George served as PPS to the Minister of State for Climate Change. He was appointed Government Adviser on Life Sciences in July 2011, working closely with the Department of Health and coordinating the Government’s Life Science and Innovation, Health and Wealth Strategies (2011), and the Agri-Tech Industrial Strategy (2013). Following that, he was appointed to the post of Prime Minister’s UK Trade Envoy.

On July 15, George was appointed as Minister for Life Sciences, a Parliamentary Under-Secretary of State at the Department of Health and Department of Business, Innovation and Skills. His mission is to make the UK the best place in the world to discover and develop 21st Century healthcare innovations.

9keynote speakers

Wel

lcom

e Co

nfer

ence

Cen

tre

- Exh

ibito

r Flo

or P

lan

Audi

toriu

m

Allo

cate

d

Exhi

bitio

n sp

aces

Tea

and

Coff e

e

Toile

tsFi

re E

xits

iH

elp

desk

Key

Avai

labl

e

15

1819

2627

65

7

8

20

25

R

432

Hin

xton

H

all

1

14 1213

Pres

s Ro

om

Part

nerin

g

i

Entr

ance

to

ON

Hel

ix Rosa

lind

Fran

klin

Pa

villi

onJa

mes

W

atso

n

Lunc

h an

d Ex

hibi

tions

21

22

2423

2816

17

30

Bar a

nd

Seat

ing

RRe

gist

ratio

n de

sk

29

Art

1011

9

Art

exh

ibits

MedImmuneAstraZenecaBioStrata MarketingWellcome Trust Sanger InstituteCambridge Respiratory Innovations (CRiL)KinapseFahy Gurteen LaboratoriesPharma Ventures BioVentures Consulting Limited Clinical Trial CompanyDiamond Pharma ServicesS-TechUnited Life SciencesArkivumInivataLiterature tableBioMed RealtyResearch Quality Association (RQA)FluidX Sigma-AldrichInnovation ForumKISS CommunicationsAbcamHorizon DiscoveryFirst Sight MediaA4PBioChesterford Research ParkAsterand Bioscience

1 and 302 and 34567891011121314151617181920212223242526272829

11floor plan and exhibitor list

Jeffrey BarrettDirector of the Centre for Therapeutic Target Validation (CTTV) Jeffrey Barrett has been involved in the CTTV since its inception in 2014 and began his role as Director on 1 May 2015. Jeff is a statistical geneticist who has led several of the largest genome-wide association studies of complex disease. He first became interested in human genetics in Mark Daly’s lab at the Whitehead Institute before moving to Lon Cardon’s group in Oxford, where he received a D. Phil in statistical genetics. Jeff was an analyst in the Well-come Trust Case Control Consortium, and led early GWAS meta-analyses in inflammatory bowel disease and type 1 diabetes while a postdoc with David Clayton in Cambridge. Since joining the Sanger Institute as a group leader in 2008, he has used next-generation sequencing in thousands of individuals to find variation associated with both rare and common human diseases.

Sir Philip CohenProfessor of Enzymology, University of Dundee Philip trained at University College, London (1963-1969) and the University of Washington, Seattle (1969-1971) before joining the University of Dundee (1971-present). He was a Royal Society Research Professor (1984-2010), Director of the MRC Protein Phosphorylation Unit (1990-2012), and Director of the Scottish Institute for Cell Signalling (2008-2012). He also directed the Division of Signal Transduction Therapy (1998-2012), Europe’s largest collaboration between a basic research institution and the pharmaceutical industry. He has been elected a Fellow of the Royal Societies of Edinburgh and London, a Foreign Associate of the US National Academy of Sciences and the Australian Academy of Sciences.

Simon CookGroup Leader, Signalling Programme & Head of Knowledge Exchange & Commercialisation, Babraham Institute Simon Cook became interested in signal transduction during his Biochemistry degree at Royal Holloway College, University of London and went on to study phospholipid signalling with Michael Wakelam at the University of Glasgow for his PhD. In 1991 he relocated to the San Francisco Bay Area to undertake post-doctoral research with Frank McCormick, first at the Cetus Corporation and then at ONYX Pharmaceuticals, where he studied the then emerging RAS-RAF-MEK-ERK1/2 pathway. After his Post-Doc he stayed on at ONYX as a Staff Scientist working on drug discovery projects. As a member of the RAS Oncogene Steering Committee he was part of the team that went on to discover sorafenib (also called Nexavar ®). In addition he was Project Manager for the Inflammation Project, which he led to partnership with Parke-Davis/Warner-Lambert (now Pfizer). In 1997 he established an independent research group at the Babraham Institute, Cambridge, UK studying the regulation of cell proliferation, senescence and cell death by protein kinase signalling pathways. From 2000-2006 he held a Cancer Research UK Senior Cancer Research Fellowship. He is currently a Group Leader in the Signalling Laboratory and Head of Knowledge Exchange and Commercialisation within the Institute. His laboratory is funded by the UK Biotechnology and Biological Sciences Research Council, the Medical Research Council, Cancer Research UK, Worldwide Cancer Research, whilst commercial collaborators include AstraZeneca and MISSION Therapeutics.

Simon’s homepage is at http://www.babraham.ac.uk/our-research/signalling/simon-cook

Jane DancerChief Operating Officer, F-star Jane Dancer joined F-star as their Chief Operating Officer in April 2012. Prior to that she was VP Business Development at Cellzome and Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)) Jane spent the first part of her career in the agrochemical industry where she held research and project management roles in Aventis Crop Science, AgrEvo UK Ltd and Schering Agrochemicals Ltd,. Jane has an MBA from The Judge Institute of Management Studies, University of Cambridge and a PhD and degree in Natural Sciences from the University of Cambridge.

12 speaker profiles

David Gann

Vice-President, Development and Innovation, Imperial College London @DavidMGann @imperialcollege

@LDN_economy @LDN_data #SmartLondon

David is responsible for shaping Imperial College’s vision, strategy and innovation agenda and development of its new White City campus. On the Executive Board, David is responsible for new ventures such as ThinkSpace, increasing and diversifying income. In 2015 he led a review of Imperial’s Technology Transfer, Translation and collaboration activities.

David holds the Chair in Innovation and Technology Management at Imperial College Business School and Department of Civil & Environmental Engineering, A Chartered Civil Engineer with a PhD in Industrial Economics, he previously held the Royal Academy of Engineering Chair in Innovative Manufacturing at Sussex University.

Hakan Goker Investment Director, MS VenturesHakan Goker (Ph.D.) is a director at MS Ventures, the corporate venture capital fund of Merck Serono. Previously, Hakan was a partner at Aescap Venture, investing in European private biotechnology and medical technology companies. Prior to Aescap, he was at Atlas Venture in London until their cessation of European operations. He was instrumental in the creation, financing, business and R&D strategy of various companies including Orphazyme (DK), F Star (NL), Actogenix (BE), Bicycle Therapeutics (UK), Nimbus Discovery (US), Lumavita (CH), Nitec now Horizon Pharma (CH/US), Protaffin (AU/UK), and Egalet (DK). Hakan received his PhD in oncology from the Institute of Cancer Research/ University of London, UK and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan is a board member of Synaffix BV and is acting CBO of Asceneuron SA.

Eric Karran Director of Research Strategy, Alzheimer’s Research UK Eric joined Alzheimer’s Research UK in 2012 and has responsibility for high-level external representation of our charity as well as driving forward our research strategy. Eric has extensive dementia research experience gained from working in the pharmaceutical industry, holding senior positions in Neuroscience drug discovery research groups (most recently Chief Scientific Officer at Janssen Pharmaceuticals in Belgium), focusing on finding therapeutics for Alzheimer’s disease. He has interacted widely with leading academic groups in the UK, Europe and the USA, as well as working with public funding agencies such as the MRC.

Jenny Laird Director, Global External R&D, Eli Lilly Jennifer Laird, Ph.D., D.Sc. is Senior Director, Search & Evaluation at Eli Lilly, based at Lilly’s European Headquarters near London. The Search & Evaluation team complements Lilly’s internal R&D efforts by evaluating and in-licensing assets and technologies, and by collaborating with external partners to advance molecules through discovery and early development. Dr. Laird joined Lilly in 2012; prior to that she spent 10 years at AstraZeneca as Executive Director heading Translational Science and Project Director leading preclinical and early development projects. Dr. Laird has a background in neuroscience, is an Editorial Board member of Neuropharmacology and European Journal of Pain and holds an honorary appointment as Professor of Pharmacology at McGill University, Canada. She received doctorates from Bristol University and University of Alicante, Spain.

13speaker profiles

12.30 Lunch and Exhibitor visits Restaurant, Hinxton Hall

Chair David Gann Imperial College London

Sir Philip Cohen University of Dundee Steve McMahon Kings College London Stuart McElroy European Screening Centre Newhouse and European Lead Factory

10.00 –10.30

11.00 - 12.30 De-risking Research: Collaborative Models

Jon Moore Horizon Discovery

13.45 - 15.15 De-risking Partnerships: Sharing Data in Collaboration

Chair Geoff Smith Illumina

Niall Martin MISSION Therapeutics Jeffrey Barrett CTTV

Jenny Laird Eli Lilly

Simon Cook Babraham Institute

Speakers

10.30 - 11.00 Coffee break and Exhibitor visits

08.00 Registration

08.45 - 08.50 Welcome from One Nucleus Jon Green Chair, One Nucleus

08.50 - 09.00 Introduction from One Nucleus Harriet Fear CEO, One Nucleus

09.00 - 09.20 Opening Keynote Address Bahija Jallal Executive Vice President of AstraZeneca and Head of MedImmune

09.20 - 09.40 Patient-led research: the case of Black Bone Disease Nicolas Sireau AKU Society

09.40 - 10.00 My Nan and her outcomes; what could have been, and what the future could hold for patients, if healthcare systems embrace digital health, data and health informatics

Farid Bidgoli Merck Sharp & Dohme

Q&A with the audience

15.15 Coffee Break and Exhibitor visits

14 programme

Speakers

15.45 - 17.00 De-risking Funding: Investing in Early Stages of Development

Chair Jane Dancer F-star

Eric Karran Alzheimer’s Research UK David Phillips SR One

Robert Tansley Cambridge Innovation Capital

Hakan Goker MS Ventures

Speakers

17.00 - 17.20 Closing Remarks George Freeman MP-Parliamentary Under Secretary of State for Life Sciences

17.20 Drinks Reception Hinxton Hall

18.30 Close

Translating UK scientifi c excellence into global therapeutic strategies

28 June 2016 Cambridge, UK

• A unique UK Translational Research Conference for the Life Science Industry

• Keynote addresses including Sir John Savill, Chief Executive, MRC

• Who Should Attend:o Biotech and Healthcare Companieso Academic Scientists and Technology Transfer Offi cers o Technical and Professional Service Providerso Life Science Investors

• An interactive case study based programme

• Practical insights on funding and collaborations in Translational Research projects

• A networking platform for Academia and BusinessOur translational research conferenceonhelix.com

Wellcome Genome Campus Conference Centre, Cambridge

15programme

Horizon is at the forefront of the personalised medicine revolution. Horizon Discovery (Horizon) is a revenue-generating international life science company that supplies c16,000 products, services and research programmes to over 1,000 customers in 50 countries. We power academic, biotech, diagnostic and pharmaceutical research by enabling a better understanding of the genetic basis of human disease and the development of targeted personalised medicines, which lead to significant improvements in outcomes for patients and the more efficient use of healthcare resources.

Powering Genomics Research and Personalised Medicine, from Sequence to Treatment

Why invest in Horizon?• Commercial offering addresses markets totalling c£29b;• Achieved a 7 year revenue CAGR of 118% driving company from IP to IPO in 6 years;• FY14 IPO raised £68.6m, a record for an AIM life science float;• FY14 revenue up 79% to £11.9m; • Delivered 2X to 32X returns on investments made; • Outperformed AIM and FTSE in 2014; and • We have a clear strategy for growth that combines sustainable growth in our core

product and service sales and accelerating revenue and profitability through M&A

Learn more about Horizon and our products and services at:

www.horizondiscovery.com

RESEARCH SERVICES

GENOMICS

DIAGNOSTICS

BIOPRODUCTION

HD 16062015 ONE Nucleus-Advert(MAY) .indd 1 6/16/2015 1:41:21 PM

Niall Martin VP Research, MISSION Therapeutics Niall Martin graduated with a PhD from Aberdeen University, from where he joined Zeneca Pharmaceuticals as a post doctorate scientist in the non-lipid cardiovascular disease Bioscience group. In 1993, Niall moved to France to become a Team Leader within the Thrombosis group at Laboratoire Fournier (Dijon, France).

On his return to the UK in 1999, Niall became Director of drug discovery at KuDOS Pharmaceuticals, Cambridge, UK where he established the drug-screening capabilities in KuDOS that underpinned all KuDOS drug discovery programmes. Most notably, Niall set up and headed the KuDOS programme against PARP (an enzyme involved in DNA repair) that yielded the pioneering new drug, olaparib, that is now in Phase I and II clinical trials. The success of this drug was a major driving force for the acquisition of KuDOS by AstraZeneca, and has underpinned the concept of synthetic lethality as a major therapeu-tic opportunity for cancer treatment. Niall then headed KuDOS from 2008 to 2010, underwhich mTOR, ATM and other DDR inhibitors were identified for AZ oncology pipeline through KuDOS. Niall is a founding member of MISSION Therapeutics and serves the company as VP Research.

Stuart McElroy

Head of Biology, European Screening Centre Newhouse and European Lead Factory Stuart gained his degree in pharmacology at Edinburgh and PhD from Strathclyde before helping to establish the Dundee Drug Discovery Unit, a small biotech style integrated drug discovery group based within Dundee University. During this time he worked on developing new drugs for neglected tropical diseases and the de - risking of novel first world targets focused on value creation through the generation of small molecules with a strong IP position. He is now head of biology at the European Screening Centre forming part of the European Lead Factory, a new platform for innovative drug discovery aiming to bridge the gap between large pharma and Europe’s academics and SMEs.

Steve McMahon Sherrington Professor for Physiology, Kings College London, Director of the London Pain Consortium and Academic Lead for EuroPain Professor Stephen McMahon is Sherrington Professor of Physiology at King’s College London. He is a Fellow of the Academy of Medical Sciences. His major research interest is pain mechanisms. He has a long standing interest in the role and potential therapeutic applications of several trophic factors, particularly the neurotrophins and the glial cell-derived neurotrophic factor family. His current research is focused on neuro-immune interactions, particularly the neurobiology of chemokines, and the genetics and epigenetics of pain. In his talk he will address some of his recent work aimed at identifying novel peripheral pain mediators. Professor McMahon directs the London Pain Consortium, a collection of leading researchers in London and Oxford working to better understand chronic pain mechanisms and improve treatments. He is also the academic lead on a EU-IMI consortium called Europain, a collaboration of scientists working in academia and industry. Professor McMahon is editor of Wall and Melzack’s Textbook of Pain, 5th and 6th Edition. He has published more than 300 research articles in scientific journals including, Nature, Nature Medicine, Nature Neuroscience, Cell, Neuron and the Journal of Neuroscience and has an H-index of 91.

Horizon is at the forefront of the personalised medicine revolution. Horizon Discovery (Horizon) is a revenue-generating international life science company that supplies c16,000 products, services and research programmes to over 1,000 customers in 50 countries. We power academic, biotech, diagnostic and pharmaceutical research by enabling a better understanding of the genetic basis of human disease and the development of targeted personalised medicines, which lead to significant improvements in outcomes for patients and the more efficient use of healthcare resources.

Powering Genomics Research and Personalised Medicine, from Sequence to Treatment

Why invest in Horizon?• Commercial offering addresses markets totalling c£29b;• Achieved a 7 year revenue CAGR of 118% driving company from IP to IPO in 6 years;• FY14 IPO raised £68.6m, a record for an AIM life science float;• FY14 revenue up 79% to £11.9m; • Delivered 2X to 32X returns on investments made; • Outperformed AIM and FTSE in 2014; and • We have a clear strategy for growth that combines sustainable growth in our core

product and service sales and accelerating revenue and profitability through M&A

Learn more about Horizon and our products and services at:

www.horizondiscovery.com

RESEARCH SERVICES

GENOMICS

DIAGNOSTICS

BIOPRODUCTION

HD 16062015 ONE Nucleus-Advert(MAY) .indd 1 6/16/2015 1:41:21 PM

17speaker profiles

Jon Moore VP Oncology and CSO, Horizon Discovery Jon joined Horizon in October 2012 to lead its oncology target validation and drug discovery collaborations and became CSO in February 2014. Prior to this, he enjoyed 10 years at Vernalis culminating in a role as Head of Biology, where he was responsible for both cell biology and assay development activities. He also led the biology side of several innovative drug discovery programs and managed a major research alliance with GSK. His current research interests concern the identification of synthetic lethal targets to exploit signaling defects in cancer. Prior to making the move to industry, he gained extensive postdoctoral experience in the cell cycle control field working with first Sally Kornbluth at Duke and then Nobel Prize winner, Tim Hunt, at Cancer Research UK’s Clare Hall labs. He holds a PhD from the University of Newcastle upon Tyne and is a Fellow of the Society of Biology.

David Phillips Partner, SR One David joined SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and subsequently joined the team focusing on European investments. David brings a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellcome, Cephalon, Medical Venture Management, The Automation Partnership and Galapagos. David has significant deal making experience in the pharmaceutical and biotech sectors and has run a number of successful businesses deriving healthy exits for investors. David has a BSc (Hons) in Pharmacology from the University of London and is a member of the Charted Institute of Marketing. David is based in London.

Robert Tansley

Investment Director for Life Sciences, Cambridge Innovation Capital Robert joined Cambridge Innovation Capital in January 2014 after 20 years’ experience in the pharma/biotech industry working both at large pharma (Sanofi, Roche), the MHRA and in VC backed companies (Arakis, KalVista) including founding the malaria therapeutics company Treague and as founding CEO of Avilex Pharma. Robert qualified in medicine at University College London and he is a member of the Royal College of Obstetricians and Gynaecologists and the Faculty of Pharmaceutical Medicine. He has an MBA from the London Business School and an MPhil in Biostatistics from the University of Cambridge.

Geoff Smith

Vice President of Product Development, Illumina Geoff Smith is Vice President for Product Development at Illumina. He has responsibility for the portfolio of programs within the Reproductive and Genetic Health business unit that spans the continuum from pre-conception testing to post-natal screening, with teams in the UK and US. He is also site lead at the RGH Cambridge site in Fulbourn. Previously, Geoff headed Technology Development for Illumina and led developments in new sequencing chemistries, systems and applications. Geoff joined Illumina through the acquisition of Solexa, a Cambridge start-up, where he led the invention and development across the sequencing workflow. Before Solexa, Geoff was Head of Research at AdProTech following postdocs at the MRC Centre for Protein Engineering, Cambridge, and HHMI, Dallas, USA. Geoff has a first degree and PhD from Cambridge University.

18 speaker profiles

genesis 2015

London’s premierLife Science & Healthcarenetworking conference

10 December 2015

QEII Centre, Westminster, London, UK

genesisconference.com

Tweet with tags #ongc15

Taking Bio-Innovation to a Global Market

BioStrata Marketing as a specialist marketing agency working in life science, our team is fluent in the languages of science and business. We combine PhD level knowledge with decades of marketing experience to develop integrated programmes that deliver results for life science companies. Everything we do starts with the development of a strategy that will help our clients succeed. As a truly integrated agency, we can then provide all of the tactical services required to help them realise their goals, from creative design and digital marketing through to content development, technical writing, social media and traditional PR tactics. We are also a leading specialist in the strategic use of cutting-edge methodologies such as inbound and content marketing.

Tel: 01223 828 200 Email: crussell@biostratamarketing.com Website: www.biostratamarketing.com Contact: Clare Russell

Stand 4

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca.com.

2 Kingdom Street, London W2 6BD, UK Tel: 020 7604 8000 www.astrazeneca.com

Partnering – see contact list at astrazeneca.com/Partnering

Communications - Esra Erkal-Paler (Esra.Erka-Paler@astrazeneca.com) / Sofia Ylén (Sofia.Ylen@astrazeneca.com) Stand 2 and 3

Abcam plc is a leading provider of protein research tools and services, with an unrivalled range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service and technical support. The Company’s catalogue of products includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits.

Stand 24

A4PBio provide CRO oversight, project management and consultancy services in bioanalysis and biologistics for the life science sector.

A4PBio offer flexible and scalable solutions in selection and oversight of global providers for pro-actively managed transport of time and temperature critical biological samples and cell-based therapies. Our expert management of bioanalytical projects includes the selection of providers, assay development and validation, study sample analysis, data reporting and document review.

A4PBio’s client-focused, flexible, scalable resources, based around our considerable Pharmaceutical, Biotechnology and CRO experience, deliver value added, cost effective, scientifically robust and regulatory compliant outsourcing or consultancy solutions.

Stand 27

21exhibitor profiles

Asterand Bioscience is the leading global provider of high quality, well characterized human tissue and human tissue-based research solutions to drug discovery scientists. Our mission is to provide human-based solutions to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with increased likelihood of clinical success. Asterand Bioscience is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical, biotechnology and diagnostic companies, as well as academia. We are focused on providing services and products to accelerate drug discovery research from target identification through to potential treatment of disease. Stand 29

Arkivum is an innovative, fast growing data archiving provider, specialising in delivering long-term archiving solutions with unique bit level preservation and an unrivalled 100% data integrity guarantee.

Since its formation in 2011, Arkivum has been steadily growing, particularly within the higher education sector as we provide archiving solutions to 1 in 3 of the top 60 universities in the UK. We are also growing in healthcare, life sciences and heritage sectors where the need to retain and provide access to large volumes of data for many years to come is also paramount.

Arkivum works with a range of partners to deliver integrated solutions for data discovery and sharing, publishing, file format preservation and information portals.

www.arkivum.com info@arkivum.com 01249 405060 Stand 15

Diamond Pharma Services comprises of four companies that provide leading edge technical services to the biotech and pharmaceutical industries through its experienced panel of employees.

• Diamond BioPharm Ltd (EU Regulatory Affairs & Product Development)

• Diamond Pharma Services, Inc. (US Regulatory Affairs & Product Development)

• Diamond PV Services Ltd (Pharmacovigilance & QPPV

• Diamond Compliance & Quality Ltd (GLP, GMP, GCP & QP Services)

With broad experience across small molecules and biologics including Advanced Therapies, we excel in supporting product development in numerous therapeutic areas to meet regulatory expectations in a timely and cost efficient manner.

info@diamondpharmaservices.com Tel: +44 (0) 1279 441 616 www.diamondpharmaservices.com Stand 12

Chesterford Research Park is home to world-leading bioscience innovators including Illumina and BioFocus. Part of the South Cambridge life sciences cluster, Chesterford’s prestigious environment and range of facilities provides flexible and future proofed modern and energy efficient laboratory and office space for both established and early stage biotechnology and pharmaceutical R&D companies. Close to the A11 and M11 this tranquil, low density development is perfectly positioned within 20 minutes of Cambridge. London is reachable in under an hour by train and Stansted airport is just 20 minutes’ drive away. Katherine Maguire, Park Manager Katherine.maguire@eu.jll.com Tel: +44 (0)1799 532252 www.chesterfordresearchpark.com Stand 28

The CLINICAL TRIAL Company™ is a full service global CRO with the experience, knowledge and enthusiasm to support medium size clinical trials and novel products which lack a classical road map to the market. The CLINICAL TRIAL Company™ has a proven record of assisting Sponsors with getting products approved. In 2012 The CLINICAL TRIAL Company’s™ was granted the Queen’s Award for Enterprise in International Trade.

The CLINICAL TRIAL Company™ has several operating divisions including The Clinical Quality Assurance Company™ (The CQA Company™), The CRA Company™, The Regulatory Affairs Company™, The CNS Company, and The Clinical Training Company™.

Audrey Jamieson, Business Development Manager, Audrey_jamieson@theclinicaltrialcompany.com Tel: +44 (0)1786 270403 www.theclinicaltrialcompany.com

Stand 11

Steve offers full project management, product development & regulatory affairs services across all development stages to the pharma industry and SMEs. Skills include:

- Managing virtual R&D programmes; & delivery via global outsourcing, partnerships & collaborations. - Leading high-value projects which require strong scientific and technical understanding. - Board level management experience. - An in-depth understanding of the needs of big pharma when in-licensing projects

Steve has over 25 years’ experience in the pharma industry (encompassing manufacturing, clinical, nonclinical, regulatory and project leadership roles). He has a PhD in Medical Biochemistry from Brunel University; and an MBA with Distinction from the Manchester Business School.

Stand 10

23exhibitor profiles

Cambridge Respiratory Innovations (CRiL) is developing the N-Tidal range of novel low-cost capnometers, based on a patented non-dispersive infra-red, fast acting sensor.

Personal variants of these advanced capnometers could be used by chronic respiratory disease sufferers to better manage their condition. CRiL expect their devices to transform the treatment of respiratory diseases by increasing patient ownership, improving the quality of life, optimising respiratory medication, minimising respiratory exacerbations, reducing avoidable hospital admissions and lowering the cost of care.

Currently CRiL has two devices under development, one for COPD and one for asthma. Independent health economics research has demonstrated that using the N-Tidal C to manage COPD could result in a saving of £60 million per year for the NHS. Stand 6

Scientists at Fahy Gurteen Laboratories have accumulated considerable know-how of high-throughput platform technologies for the discovery, development and clinical validation of cancer biomarkers.At the heart of the company are high-throughput systems for fully automated immunohistochemistry (IHC) and immunocytochemistry (ICC) staining of tumour tissues and cytospin preparation, including on-board de-paraffinisation and antigen retrieval protocols and highly sensitive polymer-based technology that allows enhanced penetration to antigens resulting in high signal amplification.The company also offer molecular pathology services like: • Tissue embedding and re-embedding• Production of multi tissue blocks• Precision microtomy• Laser-capture microdissection (LCM)• H & E and special stains• Automated IHC and Digital Image

analysis• Automated and manual IHC staining on

human and animal FFPE tissue, and cell block samples

• IHC optimisation on control tissues Stand 8

Our translational research conference

Translating UK scientifi c excellence into global therapeutic strategies

onhelix.com

28 June 2016 Cambridge, UK

Kinapse Ltd provides expert advisory, capability building and operational services to the life sciences industries. Our mission statement is: ‘Collaborating with our clients to innovate for exceptional results’. Kinapse clients include many of the world’s leading pharmaceutical, biotechnology, medical device and specialty pharmaceutical companies, government organisations and life sciences service providers. Our key advantages include:

•Focusonthelifesciencesindustries

•Deepindustryexperienceandtechnicalacumen

•Historyofsuccessfulprojectdelivery.

Andy Black, CEO, info@kinapse.com Tel: +44 208 946 7600 www.kinapse.com

Stand 7

Innovation Forum is a global network of innovative companies, entrepreneurs, investors, researchers and policy makers with branches in Europe, Asia and North America. This gives us a unique ability to think and act in an international, cross-cultural context and enable global synergies for our members and partners.

We help early stage technologies to reach the market place faster. Whether you are an early stage start-up or a multinational corporation we act as an accumulator accelerator and broker of ideas and talent to help you innovate.

We connect thousands of innovative minds across 14 global locations. To learn more and become a member please visit: www.inno-forum.org

Stand 22

Inivata is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment.

Inivata works with leaders in industry and academic research to develop new clinical applications for ctDNA analysis which will bring real benefits to physicians, patients, pharmaceutical companies and payers. Inivata’s goal is to provide physicians with the information they need, to provide the best outcomes for patients and effective design for clinical trials.

Stand 16

Horizon Discovery is a UK Biotechnology company that combines a long scientific heritage in translational research with a precision gene-editing platform that incorporates rAAV, CRISPR and ZFN technologies. The company supplies genetically-defined cell lines, gene-editing tools and services, custom cell line generation, in vivo models, reporter gene assay kits, molecular reference standards and assay development and screening services to over 1,000 organisations engaged in academic research; drug discovery and development; clinical diagnostics; and biopharmaceutical process optimization. Horizon aspires to provide science-driven research solutions that lead to the advancement in the understanding of the genetic basis of disease and better outcomes for patients.

Stand 25

FluidX is a sample storage and tracking specialists. The team at FluidX probably knows more about 2D storage tubes and readers than any other group in the world. FluidX manufactures an ever-developing range of 2D barcoded sample storage tubes along with tube sorting and tube tracking systems. The needs of our customers are always placed first, right in the heart of our business, therefore our products and services continually evolve to meet the requirements of an ever-changing environment. Understanding the balance between the need for reliability and precision combined with budget constraints, FluidX always strives to offer superior products at competitive prices.

Stand 20

First Sight Media are professional video production and streaming specialist, who have been delivering creative live events, training and promotional videos for over 20 years. Specialising in live and on-demand video streaming, communicating your message through us, over the internet has never been easier.

We also offer the ability for you to enhance your conferences and webinars through our bespoke presentation software iPresenter, allowing you to deliver high definition video of your speaker simultaneously with their presentation slides online.

Whatever your audience, we can offer a tailored solution to effectively communicate your message through creative multimedia. Visit our website to see examples and get in touch.

W: www.firstsightmedia.co.uk E: mikegilham@firstsightmedia.co.uk Contact: Mike Gilham - Sales Director Tel No 0800 072 8753

Stand 26

25exhibitor profiles

Sigma-Aldrich, a leading Life Science and High Technology company focused on enhancing human health and safety, manufactures and distributes more than 230,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units – Research, Applied and SAFC Commercial – Sigma-Aldrich is committed to enabling science to improve the quality of life.

Stand 21

Research Quality Association (RQA) is a not-for-profit international membership association with members in 55 countries throughout the world. We provide status and visibility for individuals concerned with the quality of research in pharmaceuticals, agrochemicals, chemicals and medical devices. Our membership is made up of quality professionals including managers, scientists, auditors and other practitioners worldwide. They are concerned with the quality and compliance of research and development with a particular focus upon the safety and efficacy of pharmaceuticals, biologicals, devices, agrochemicals and chemicals in man, animals and the environment.

Visit our website to view our extensive range of services/products.

Tony Ward, tward@therqa.com Tel: +44 (0)1473 221411 www.therqa.com

Stand19

S-Tech has supported the biotech and life science related industries since 1982 by arranging insurance cover against a wide range of asset, liability and financial risks. We work with you to fully understand your business to achieve the widest possible insurance protection. We are a fully independent and Chartered Insurance Broker with access to insurance markets in the UK, Lloyds and overseas. Our clients range from start-up to international organisations both in the UK and abroad. We offer a wide range of services to One Nucleus members; please check the Support Supplier page or search for S-Tech on the One Nucleus website.

Stand 13

KISS is the creative agency that clarifies the complex. We are experts at immersing ourselves in the complex things you do to emerge with focus and clarity to create ideas that will worry your competition.

With specific and in-depth expertise working across the Science, Technology, and Healthcare sectors, our ability to cut through complexity and successfully deliver a single-minded proposition has been instrumental in us winning a fantastic family of blue chip, SME and disruptive start up clients.

KISS is a member of the PROI, the world’s largest partnership of independent agencies. This gives us access to the leading independent agencies in 100 cities across 5 continents, offering local knowledge to deliver global results via international marketing and PR campaigns.

John Dibb, john@kisscom.co.uk T: 01223 911 123

Stand 23

26 exhibitor profile

MedImmune is the worldwide biologics R&D arm of AstraZeneca with headquarters in Gaithersburg, Maryland (US). MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. MedImmune has a robust pipeline of over 120 biologic medicines in R&D, with more than 30 in clinical stage development and marketed products including Synagis® (palivizumab) and Fluenz® (live attenuated influenza vaccine, LAIV). Employing approximately 500 people, MedImmune’s Cambridge site is a major R&D hub supporting the research and early development of the biologics portfolio.

Tel: 01223 471 471 www.medimmune.com John Elvin, elvinj@medimmune.com

Stand 1 and 30

PharmaVentures is a premier transaction advisory firm; a world-leader in partnering, M&A deals and strategic alliances. Our bank of specialist experience, deal analytics and network of contacts makes us uniquely placed to support you in all aspects of deal making and strategic planning. PharmaVentures is known for its deep insight into deal structures and success for generating partnering interest. Services include: M&A (divestments, mergers, acquisitions and strategic transactions); strategy (commercialisation, deal strategy, due diligence, market entry); valuation and positioning (licensing, M&A, fund raising and expert testimonies); licensing (in and out licensing); expert testimony (patent infringement, deal disagreements, taxation, determining damages). Tel: 01865 332 700

Email: enquiries@pharmaventures.com Website: www.pharmaventures.com Contact: Fiona Gardner Stand 9

United Life Sciences (ULS) is a strategic partnership representing over 1,000 life science and healthcare organisations across the UK and internationally. The ULS collaboration has member and the wider UK life science sector benefit at the heart of its purpose and is the basis for all joint activities. It strives to avoid duplication of effort and coordinates the five organisations’ activities whilst recognising each other’s areas of strength so that member companies can benefit from more effective and coherent sector support.

One Nucleus - Harriet Fear, harriet@onenucleus.com

BIA – Steve Bates, SBates@bioindustry.org

Bionow - Geoff Davison, geoff.davison@bionow.co.uk

BioPartner - Lin Bateson, lin@biopartner.co.uk

MediWales - Debbie Laubach, debbie.laubach@mediwales.com Stand 14

The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research programmes are being used to develop new diagnostics and treatments for human disease.

The Institute is based at the Wellcome Genome Campus, a world class hub for genomics and bioinformatics. Spring 2016 sees the opening of its Biodata Innovation Centre, enabling a growing number of commercial sector collaborators to join its shared vision of delivering life changing science. Contact: Campus Business Development Office Telephone: +44(0)1223 494895 Email: info@wellcomegenomecampus.org

Stand 5

Life Science Leadership Series

Strategies of Funding and Clinicial Trials24 September

2015

Chesterford Research Park, Cambridge, UKonenucleus.com

One Nucleus Limited

CambridgeThe PortwayGranta Park Cambridge CB21 6GSUnited Kingdom

+44 (0) 1223 896 450

info@onenucleus.comonenucleus.com